CRISPR Therapeutics (CRSP)

Company Profile

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Company profile

Ticker

CRSP

Exchange

NASDAQ

Website

www.crisprtx.com

CEO

Samarth Kulkarni

Incorporated

Switzerland

Location

Switzerland

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...

SEC CIK

0001674416

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

CRISPR Therapeutics, Inc. • TRACR Hematology Ltd • CTX Financing GmbH • CTX Securities Corporation ...

CRSP stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$75.26

Low target

$39.00

High target

$123.00

Latest filings (excl ownership)

View all

8-K

CRISPR Therapeutics Announces Transition of Chief Financial Officer

21 Feb 23

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

1 Nov 22

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

1 Nov 22

8-K

CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer

27 Oct 22

8-K

Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

27 Sep 22

S-8

Registration of securities for employees

8 Aug 22

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

8 Aug 22

Latest ownership filings

View all

Capital International Investors

13 Feb 23

Financial summary

Financial statements Chart CRSP financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	223.52 mm	223.52 mm	223.52 mm	223.52 mm	223.52 mm	223.52 mm
Cash burn (monthly)	94.25 mm	59.70 mm	43.85 mm	56.10 mm	37.78 mm	41.31 mm
Cash used (since last report)	252.00 mm	159.63 mm	117.23 mm	149.99 mm	101.00 mm	110.46 mm
Cash remaining	-28.48 mm	63.89 mm	106.29 mm	73.53 mm	122.52 mm	113.06 mm
Runway (months of cash)	-0.3	1.1	2.4	1.3	3.2	2.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

CRSP institutional ownership history Ownership history

93.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	397	432	-8.1%
Opened positions	54	56	-3.6%
Closed positions	89	59	+50.8%
Increased positions	115	121	-5.0%
Reduced positions	113	113	–

13F shares	Current	Prev Q	Change
Total value	2.25 tn	4.75 bn	+47400.0%
Total shares	73.37 mm	72.22 mm	+1.6%
Total puts	1.73 mm	2.35 mm	-26.5%
Total calls	1.92 mm	2.51 mm	-23.5%
Total put/call ratio	0.9	0.9	-4.0%

Largest owners	Shares	Value	Change
ARK Investment Management	7.83 mm	$318.29 bn	-4.9%
VRTX Vertex Pharmaceuticals	5.38 mm	$353.37 mm	0.0%
Capital International Investors	5.35 mm	$217.66 bn	+0.2%
CMTDF Sumitomo Mitsui Trust	4.01 mm	$162.86 bn	-6.0%
Nikko Asset Management Americas	4.01 mm	$162.86 bn	-6.0%
GSK GSK	3.31 mm	$278.46 mm	0.0%
T. Rowe Price Investment Management	2.99 mm	$122.79 bn	+33.6%
Bayer Global Investments B.V.	2.95 mm	$154.89 mm	0.0%
CELG Celgene	2.80 mm	$116.71 mm	0.0%
BLK Blackrock	2.63 mm	$106.90 bn	+12.1%

Largest transactions	Shares	Bought/sold	Change
STT State Street	2.08 mm	+2.08 mm	NEW
BAC Bank Of America	426.52 k	-1.04 mm	-71.0%
MCQEF Macquarie	39.94 k	-797.49 k	-95.2%
T. Rowe Price Investment Management	2.99 mm	+752.13 k	+33.6%
Norges Bank	715.43 k	+715.43 k	NEW
ARK Investment Management	7.83 mm	-407.19 k	-4.9%
BLK Blackrock	2.63 mm	+283.15 k	+12.1%
BCS Barclays	389.68 k	+280.91 k	+258.3%
PEAK6 Investments	271.85 k	+271.85 k	NEW
Frontier Capital Management	55.87 k	-263.04 k	-82.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CRSP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Mar 23	Raju Prasad	Stock Option Common Shares	Grant	Acquire A	No	No	45.15	100,000	4.52 mm	100,000
14 Mar 23	Raju Prasad	RSU Common Shares	Grant	Acquire A	No	No	0	40,000	0.00	40,000
13 Mar 23	Kasinger James R.	Common Shares	Payment of exercise	Dispose F	No	No	43.22	1,022	44.17 k	54,844
13 Mar 23	Kasinger James R.	Common Shares	Payment of exercise	Dispose F	No	No	43.22	1,283	55.45 k	53,616
13 Mar 23	Samarth Kulkarni	Common Shares	Payment of exercise	Dispose F	No	No	43.22	4,086	176.60 k	387,377
13 Mar 23	Samarth Kulkarni	Common Shares	Payment of exercise	Dispose F	No	No	43.22	5,358	231.57 k	382,463
11 Mar 23	Kasinger James R.	Common Shares	Option exercise	Acquire M	No	No	0	2,250	0.00	55,866
11 Mar 23	Kasinger James R.	RSU Common Shares	Option exercise	Dispose M	No	No	0	2,250	0.00	4,500
11 Mar 23	Samarth Kulkarni	Common Shares	Option exercise	Acquire M	No	No	0	9,000	0.00	391,463
11 Mar 23	Samarth Kulkarni	RSU Common Shares	Option exercise	Dispose M	No	No	0	9,000	0.00	18,000